HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TYK MEDICINES-B

14.040

+0.3602.63%

Volume:2.35M

Turnover:32.55M

Market Cap:5.34B

PE:-11.19

High:14.250

Open:13.600

Low:13.500

Close:13.680

52wk High:56.550

52wk Low:13.000

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:2.48

T/O Rate:0.63%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.255

ROE:--

ROA:-27.71%

PB:13.65

PE(LYR):-11.19

PS:45542.09

Loading ...

Overview Company News Filings

TYK Medicines, Inc. (02410) Announces Monthly Return on Movements in Securities for October 2025

Bulletin Express

TYK Medicines, Inc. (TYK) Announces Articles of Association (October 2025)

Bulletin Express

TYK Medicines (2410) Releases 2025 Second EGM Poll Results

Bulletin Express

TYK Medicines Inc. Held Extraordinary General Meeting

HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting

Financial Insights on Hong Kong Stocks | Severe Price Correction in Gold and Silver, Institutions Affirm Strong Fundamental Support for Precious Metal Rally

TYK Medicines, Inc. (2410) Announces Positive CDK Inhibitor Data at ESMO 2025

Bulletin Express

TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025

TYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025

TYK MEDICINES-B (02410) Proposes Adoption of 2025 H-Share Incentive Plan

TYK Medicines Inc. to Vote on Abolishing Board of Supervisors, Amending Articles, and Adopting 2025 H Share Incentive Scheme at Next Shareholder Meeting

Have TYK Medicines Insiders Been Selling Stock?

Simply Wall St.

TYK MEDICINES-B (02410): Zhang Senquan Resigns as Independent Non-Executive Director

TYK Medicines Inc. Announces Resignation of Independent Director, Faces Temporary Non-Compliance with Listing Rules

Alotinib's Pivotal Phase II Clinical Results Selected for WCLC Oral Presentation, TYK MEDICINES-B (02410)'s Differentiated Innovation Value Gains International Academic Recognition

Stock Track | TYK Medicines Plummets 5.66% Despite Narrowed H1 Loss as Revenue Remains Elusive

TYK Medicines Inc. Reports No Revenue or Sales, Increases in Other Income and Gains for H1 2025

TYK Medicines Inc. Expands Operations with Strategic Investment in Wealth Management Products

TYK MEDICINES-B (02410): Meng Xiaoying Resigns as Non-Executive Director

TYK MEDICINES-B (02410) Significantly Narrows Net Loss in First Half, Steady Progress in Commercialization Layout and Gradual Establishment of Industrial Production System

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02410/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":14.04,"timestamp":1763091197694,"preClose":13.68,"halted":0,"volume":2349000,"delay":0,"floatShares":375457818,"shares":380065818,"eps":-1.2550657026655376,"marketStatus":"Trading","change":0.36,"latestTime":"11-14 11:33:19","open":13.6,"high":14.25,"low":13.5,"amount":32550515,"amplitude":0.054825,"askPrice":14.05,"askSize":5500,"bidPrice":14,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.8452302287188173,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1763092800000},"marketStatusCode":2,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":13.68,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":2.478736,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-27.71%","roe":"--","lyrEps":-1.255066,"volumeRatio":2.478736,"shares":380065818,"dividePrice":0,"high":14.25,"amplitude":0.054825,"preClose":13.68,"low":13.5,"week52Low":13,"pbRate":"13.65","psRate":"45542.09","week52High":56.55,"institutionHeld":0,"latestPrice":14.04,"committee":-0.222222,"eps":-1.2550657026655376,"divideRate":0,"volume":2349000,"delay":0,"ttmEps":-0.8452302287188173,"open":13.6,"prevYearClose":47.15,"prevWeekClose":14.24,"prevMonthClose":15.32,"prevQuarterClose":16.54,"fiveDayClose":14.24,"twentyDayClose":16.11,"sixtyDayClose":18.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1747324800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2025-11-13","current":-16.079369,"percent":0.8,"low":-45.171338,"twenty":-25.322331,"median":-19.784348,"eighty":-16.950558,"high":-10.104382,"avg":-21.784532,"sd":6.302445,"marketCap":5199300390},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-13","current":-16.950558,"twenty":-25.322331,"median":-19.784348,"eighty":-16.950558,"marketCap":5199300390}],"updateTime":1763085217721},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1117396766","title":"TYK Medicines, Inc. (02410) Announces Monthly Return on Movements in Securities for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1117396766","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117396766?lang=en_us&edition=fundamental","pubTime":"2025-11-04 16:46","pubTimestamp":1762246003,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (the “Company”) (02410) reported no changes to its registered H share capital and unlisted share capital for the month ended 31 October 2025. The registered H share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1170971249","title":"TYK Medicines, Inc. (TYK) Announces Articles of Association (October 2025)","url":"https://stock-news.laohu8.com/highlight/detail?id=1170971249","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170971249?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:49","pubTimestamp":1761832156,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (Chinese name: 浙江同源康醫藥股份有限公司) released its updated Articles of Association dated October 2025. According to the document, TYK Medicines, Inc. is a joint stock limited company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1155308138","title":"TYK Medicines (2410) Releases 2025 Second EGM Poll Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1155308138","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155308138?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:26","pubTimestamp":1761830806,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc (Stock Code: 2410) held its 2025 second extraordinary general meeting (EGM) on October 30, 2025, in Shanghai. The meeting was chaired by the Chairman of the Board, and attended by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"2579226119","title":"TYK Medicines Inc. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579226119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579226119?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:18","pubTimestamp":1761819527,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. held its 2025 second extraordinary general meeting on October 30, 2025. The meeting included proposals put forward to shareholders. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLc1BBc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"1195241532","title":"HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1195241532","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195241532?lang=en_us&edition=fundamental","pubTime":"2025-10-28 11:56","pubTimestamp":1761623776,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million. The company recently announced that early clinical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","09939","BK1161","BK1515","02410","BK1574"],"gpt_icon":0},{"id":"1117330990","title":"Financial Insights on Hong Kong Stocks | Severe Price Correction in Gold and Silver, Institutions Affirm Strong Fundamental Support for Precious Metal Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1117330990","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117330990?lang=en_us&edition=fundamental","pubTime":"2025-10-22 07:50","pubTimestamp":1761090630,"startTime":"0","endTime":"0","summary":"Today’s headlines indicate a steep correction in gold and silver prices, with international gold and silver witnessing significant declines. Spot gold dropped 5.18% to $4,130.41 per ounce, marking...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"70c4ec2eb3fbd1c377984904e60ac1b1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1536","LU0164880469.USD","00728","LU0359201885.HKD","BK1190","LU0348766576.USD","BK4613","LU2063271972.USD","LU0173614495.USD","LU0572944931.SGD","QOmain","BK1602","02477","BK0012","LU2360107168.USD","LU0287142896.SGD","LU0499858438.USD","LU0164865239.USD","LU0823426308.USD","518880","LU0231483743.USD","LU2087625088.SGD","BK1116","BK4539","LU2543165471.USD","BK1161","LU0345776255.USD","159934","LU2250418816.HKD","LU0871576103.HKD","LU1861220033.SGD","LU0611395673.USD","IAU","BK4023","LU1960683339.HKD","SG9999002950.SGD","BK0188","LU0307460666.USD","LU1807302812.USD","BK1610","09992","APP","BK1601","LU0211977185.USD","LU0823426480.USD","NUGT","LU1993786604.SGD","MGCmain","BK0028","BK1133","LU0531971595.HKD","BK1506","LU1852331112.SGD","BK1538","BK1502","SGXZ62798434.SGD","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","BK4608","LU0345775950.USD","BK4588","LU0353189680.USD","GLD","SGXZ86797644.SGD","LU0056508442.USD","BK1221","BK0215","02498","01088","LU2360106780.USD","BK1505","GCmain","SGUmain","SGCmain","BK1224","LU1770036033.HKD","BK1545","LU1023057109.AUD","02410","BK4585","BK1155","03750","01208","LU1481107354.HKD","LU0097036916.USD","SG9999001069.SGD","LU0499858602.USD","BK1589","GDX","BK1178","BK1566","IE00B894F039.SGD","00590","LU2290526834.HKD","LU0149721374.USD","BK1179","BK1594","LU0348767384.USD","1OZmain","LU0359202008.SGD","IE0034224299.USD","LU0327786744.USD","LU0593848301.USD","IE00B19Z9P08.USD","BK1592","LU0039217434.USD","LU0588546209.SGD","LU0359201612.USD","000729","DUST","LU1861215975.USD","00392"],"gpt_icon":1},{"id":"1194507614","title":"TYK Medicines, Inc. (2410) Announces Positive CDK Inhibitor Data at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1194507614","media":"Bulletin Express","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194507614?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:22","pubTimestamp":1761049352,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (Stock Code: 2410) presented early-phase clinical study findings for three cyclin-dependent kinase (CDK) inhibitor candidates—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"2577820680","title":"TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577820680","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577820680?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:15","pubTimestamp":1761048917,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase  inhibitor candidates: TYK-00540 , TY-2699a , and TY-302 . The data were presented as posters at the European Society for Medical Oncology  Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL7sF17S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"1149235188","title":"TYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1149235188","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149235188?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:14","pubTimestamp":1761048849,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","BK1161","09939","02410"],"gpt_icon":0},{"id":"1102423374","title":"TYK MEDICINES-B (02410) Proposes Adoption of 2025 H-Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1102423374","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102423374?lang=en_us&edition=fundamental","pubTime":"2025-10-14 22:50","pubTimestamp":1760453414,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that the board of directors proposes to adopt the 2025 H-share incentive plan.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1515","09939","BK1161","BK1574","159938"],"gpt_icon":0},{"id":"2575214923","title":"TYK Medicines Inc. to Vote on Abolishing Board of Supervisors, Amending Articles, and Adopting 2025 H Share Incentive Scheme at Next Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2575214923","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575214923?lang=en_us&edition=fundamental","pubTime":"2025-10-14 22:47","pubTimestamp":1760453245,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. to Vote on Abolishing Board of Supervisors, Amending Articles, and Adopting 2025 H Share Incentive Scheme at Next Shareholder Meeting. TYK Medicines Inc. has announced that it will send shareholders a proxy proposal for a vote at its upcoming general meeting. The proposal covers amendments to the Articles of Association, the abolishment of the Board of Supervisors, amendments to the rules of procedure for the Board of Directors and shareholders' meetings, and the adoption of the 2025 H Share Incentive Scheme. The company recommends that shareholders vote in favor of the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on Octobe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL6lNHVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"gpt_icon":0},{"id":"2569473272","title":"Have TYK Medicines Insiders Been Selling Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569473272","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569473272?lang=en_us&edition=fundamental","pubTime":"2025-09-22 08:25","pubTimestamp":1758500743,"startTime":"0","endTime":"0","summary":"We'd be surprised if TYK Medicines, Inc ( HKG:2410 ) shareholders haven't noticed that the Non-Executive Director, Eric...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/have-tyk-medicines-insiders-been-selling-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/have-tyk-medicines-insiders-been-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","BK1161","02410"],"gpt_icon":0},{"id":"1146445584","title":"TYK MEDICINES-B (02410): Zhang Senquan Resigns as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1146445584","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146445584?lang=en_us&edition=fundamental","pubTime":"2025-09-15 17:16","pubTimestamp":1757927781,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that Mr. Zhang Senquan has submitted his resignation as Independent Non-Executive Director of the company to devote more time to other business affairs, effective...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","09939","BK1515","BK1161","BK1574","159938"],"gpt_icon":0},{"id":"2567197636","title":"TYK Medicines Inc. Announces Resignation of Independent Director, Faces Temporary Non-Compliance with Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2567197636","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567197636?lang=en_us&edition=fundamental","pubTime":"2025-09-15 17:15","pubTimestamp":1757927709,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. announced that Mr. Zhang Senquan has resigned from his position as an independent non-executive director, effective September 15, 2025, to focus on other business endeavors. His departure also sees him stepping down as chairman of the audit committee and as a member of the remuneration and appraisal committee and the nomination committee. The company is currently in temporary non-compliance with certain listing rules following his resignation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLnfGDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TYK Medicines Inc. Announces Resignation of Independent Director, Faces Temporary Non-Compliance with Listing Rules","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"1194257641","title":"Alotinib's Pivotal Phase II Clinical Results Selected for WCLC Oral Presentation, TYK MEDICINES-B (02410)'s Differentiated Innovation Value Gains International Academic Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=1194257641","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194257641?lang=en_us&edition=fundamental","pubTime":"2025-09-11 15:34","pubTimestamp":1757576074,"startTime":"0","endTime":"0","summary":"Recently, the highly anticipated 2025 World Conference on Lung Cancer (WCLC) was held in Barcelona, Spain. As the world's largest and most influential academic conference in the lung cancer field, it...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","09939","BK1515","BK1161","BK1574","159938"],"gpt_icon":0},{"id":"1127970721","title":"Stock Track | TYK Medicines Plummets 5.66% Despite Narrowed H1 Loss as Revenue Remains Elusive","url":"https://stock-news.laohu8.com/highlight/detail?id=1127970721","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127970721?lang=en_us&edition=fundamental","pubTime":"2025-09-01 12:22","pubTimestamp":1756700543,"startTime":"0","endTime":"0","summary":"TYK Medicines (HKG:2410) saw its stock price plummet by 5.66% during Monday's intraday trading session, despite reporting improved financial results for the first half of 2025. The pharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02410"],"gpt_icon":0},{"id":"2563858251","title":"TYK Medicines Inc. Reports No Revenue or Sales, Increases in Other Income and Gains for H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2563858251","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563858251?lang=en_us&edition=fundamental","pubTime":"2025-08-31 18:57","pubTimestamp":1756637843,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. has announced its interim results for the six months ended June 30, 2025. The company reported no revenue or cost of sales for the period. The gross profit was impacted by other income and gains totaling a loss of RMB 20.82 million, compared to a loss of RMB 11.29 million during the same period in 2024. Research and development costs were reduced to RMB 88.76 million from RMB 137.76 million in 2024. Administrative expenses slightly decreased to RMB 38.78 million from RMB 40.10 million in the previous year. No dividends were paid or declared during this period. In terms of business operations, TYK Medicines Inc. highlighted significant progress with its core product, TY-9591. The company completed patient enrollment for a pivotal Phase II clinical trial of TY-9591 monotherapy in brain metastases from lung cancer with EGFR mutations, qualifying for conditional marketing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nNDL4CWSSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"2563858268","title":"TYK Medicines Inc. Expands Operations with Strategic Investment in Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2563858268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563858268?lang=en_us&edition=fundamental","pubTime":"2025-08-31 18:57","pubTimestamp":1756637833,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc., a joint stock company based in the People's Republic of China, has announced its strategic expansion into wealth management by subscribing to a series of financial products. The company, known for its focus on pharmaceutical development, has subscribed to five wealth management products from China CITIC Bank as part of its treasury operations. This move is aimed at enhancing the allocation of financial resources and increasing the utilization efficiency of idle funds, thereby boosting overall profitability and ensuring better investment returns for shareholders. The expansion into wealth management products aligns with TYK Medicines Inc.'s commitment to maintaining high security and liquidity in its financial operations while supporting its core business activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nNDL729YFs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1230","BK0028","BK0187","BK1161","00267","BK0278","BK0188","BK0012","BK0201","601998","BK0183","BK0015"],"gpt_icon":0},{"id":"1127482693","title":"TYK MEDICINES-B (02410): Meng Xiaoying Resigns as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1127482693","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127482693?lang=en_us&edition=fundamental","pubTime":"2025-08-31 18:50","pubTimestamp":1756637420,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that Dr. Meng Xiaoying has submitted her resignation as a non-executive director of the company, effective from August 31, 2025, in order to devote more time to other business commitments.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161","BK1574","159938","09939","BK1515"],"gpt_icon":0},{"id":"1125652602","title":"TYK MEDICINES-B (02410) Significantly Narrows Net Loss in First Half, Steady Progress in Commercialization Layout and Gradual Establishment of Industrial Production System","url":"https://stock-news.laohu8.com/highlight/detail?id=1125652602","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125652602?lang=en_us&edition=fundamental","pubTime":"2025-08-31 18:46","pubTimestamp":1756637187,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced its 2025 interim results, showing research and development costs of RMB 88.758 million, narrowing by 35.6% year-on-year; administrative expenses of RMB 38.775...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161","BK1574","159938","09939","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}